Entries |
Document | Title | Date |
20080200540 | ANTIPARASITIC AGENTS - The present invention relates to compounds of the formula (I) | 08-21-2008 |
20080200541 | Benzofuranyl Alkanamine Derivatives and Uses Thereof - Compounds of formula I or pharmaceutically acceptable salts thereof are provided: | 08-21-2008 |
20080255229 | Parenteral solution containing amiodarone in NNDMA (N,N,-Dimethylacetamide) - Disclosed herein are parenteral solutions containing 3-diethylaminoethoxy benzoyl-benzofurans, such as amiodarone, in a diluent NNDMA (N,N-Dimethylacetamide) useful in the treatment of cardiac arrhythmias both supraventricular, ventricular as well as, the condition of cardiac arrest. | 10-16-2008 |
20080255230 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES - Disclosed herein is compound having a formula | 10-16-2008 |
20080280976 | Composition Comprising the Alcohol Compound Isolated from the Extract of Cucurbitaceae Family Plant Having Anti-Adipogenic and Anti-Obesity Activity - The present invention is related to an alcohol compound isolated from the extract of Cucurbitaceae family plant having anti-adipogenic and anti-obesity activity, and a composition comprising the same. The compound showed potent reducing activity of body weight, decreasing effect on the blood triglyceride and cholesterol level, activating activity of PPAR α and preventing activity from the adipogenesis of precursor fat cells with no toxicity, therefore, those extract can be useful in treating or preventing obesity and adipogenesis-involved diseases as a medicine or health care food. | 11-13-2008 |
20080312318 | DEUTERIUM-ENRICHED ESCITALOPRAM - The present application describes deuterium-enriched escitalopram, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 12-18-2008 |
20090030073 | PLANT-DERIVED THERAPEUTIC AGENT FOR MALIGNANT - A therapeutic agent for a malignant tumor containing a compound represented by the following formula (1) or (2): | 01-29-2009 |
20090048336 | ESCITALOPRAM OXALATE POWDERS - Escitalopram oxalate powders having definite particle size distribution parameters, processes for preparing the powders, and solid pharmaceutical formulations containing the powders. | 02-19-2009 |
20090062382 | EXTERNAL PREPARATION FOR IMPROVING COITAL FUNCTION - The present invention provides a preventive or a remedy for penile erectile dysfunction, which promotes blood-flow in a penile sponge body over long time and thus induces erection while showing high safety without any adverse effect on a body as a whole, when externally administered to a penis. | 03-05-2009 |
20090069417 | CAROTENOID OXIDATION PRODUCTS AS CHEMOPREVENTIVE AND CHEMOTHERAPEUTIC AGENTS - The present invention relates to a method for the chemoprevention and treatment of cancer, by administering a pharmaceutical composition comprising a carotenoid derivative, such as a derivative of lycopene, a- and b-carotene, phytoene, phytofluene, lutein, zeaxanthin, α- and β-cryptoxanthin, canthaxanthin, astaxanthin, or other carotenoid. The carotenoid derivative is a carotenoid oxidation product, and is preferably an aldehyde derivative, a dialdehyde derivative or a ketone derivative. The carotenoid derivative can be a derivative of any naturally occurring carotenoid, such as those found in tomatoes and other fruits and vegetables. | 03-12-2009 |
20090076137 | DEUTERIUM-ENRICHED DRONEDARONE - The present application describes deuterium-enriched dronedarone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090076138 | DEUTERIUM-ENRICHED DARUNAVIR - The present application describes deuterium-enriched darunavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090082434 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same - Compounds of Formula 1 or pharmaceutically acceptable salts thereof are provided: | 03-26-2009 |
20090088468 | NOVEL EPOPROSTENOL FORMULATION AND METHOD OF MAKING THEREOF - This invention relates to a stable epoprostenol composition that can be combined with commercially available IV fluids and can be administered in its reconstituted and/or diluted form under ambient conditions of about 15-30° C. for greater than 24 hours. The composition preferably contains (a) epoprostenol or a salt thereof; (b) a alkalinization agent; and (c) a base, such that when reconstituted or in solution, the solution has a pH>11. Methods for making the lyophilized composition are also disclosed. | 04-02-2009 |
20090105333 | MELATONIN AGONIST TREATMENT - This invention provides methods of administering (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclo-propyl]methyl]propanamide as a melatonin receptor agonist to a human subject to treat or prevent a circadian rhythm disorder or sleep disorder. | 04-23-2009 |
20090124687 | Benzofuran Compound and Pharmaceutical Composition Containing the Same - The present invention relates to a compound having a leukotriene (particularly leukotriene B4) inhibitory action, and useful for the prophylaxis or treatment of diseases such as allergy, asthma, inflammation, cancer and the like. | 05-14-2009 |
20090163585 | Carbosulfane-Based Pesticidal Compositions, Process for Preparing Same, Process for Controlling Insects/Mites/Nematodes, and Use of Said Compositions - The present invention relates to pesticidal compositions comprising 2,3-dihydro-2,2-dimethylbenzofuran-7-yl(dibutylaminothio)methylcarbamate, namely benzofuranyl methylcarbamate, commonly known as carbosulfane, of structural formula (I). The present invention deals more particularly with compositions comprising this active compound at a high concentration, which makes it the most economical product for sale, more stable during storage and more effective in small quantities, and it may be further combined with one or more inerts. The present invention further discloses a process for preparing said compositions and a process for controlling insects/mites/nematode. The applications for these formulations include the treatment of seeds and leaves. In the latter case, in addition to the diluting agent, a mixture of anionic and non-ionic surfactants have been included in the formulation, so that the solution will become self-emulsifying upon being added to water. | 06-25-2009 |
20090163586 | Bis-(Sulfonylamino) Derivatives in Therapy 205 - The invention provides compounds of formula (I) | 06-25-2009 |
20090170931 | EP2 and EP4 agonists as agents for the treatment of influenza a viral infection - The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof. | 07-02-2009 |
20090209638 | TREATMENT FOR DEPRESSIVE DISORDERS - A method of treating depression comprising administering a melatonin agonist. | 08-20-2009 |
20090221699 | Fab I Inhibitors - Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections. | 09-03-2009 |
20090264522 | METHODS OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH A LOW DOSE COMBINATION OF ESCITALOPRAM AND BUPROPION - The present invention relates to a method of treating a central nervous system disorder, such as a mood disorder (e.g., major depressive disorder) or an anxiety disorder (e.g., general anxiety disorder, social anxiety disorder, post traumatic stress disorder, and panic disorder) with a low dose combination of escitalopram and bupropion. | 10-22-2009 |
20090270496 | ANTIFUNGAL COMPOUNDS - Antifungal compounds having a benzofuran structure. Antifungals exhibit much less toxicity to human cells than amiodarone. These compounds are useful alone or in combination with other compounds having antifungal activity. Compounds of this invention exhibit synergistic antifungal activity in combination with antifungal amiodarone compounds. The invention provides pharmaceutical compositions useful for treating fungal infections, methods for treating fungal infections and compounds useful in such compositions for treating fungal infections. Compounds of this invention are further useful as antifungal agents for the prevention and or treatment of fungal infections in plants. The invention includes agriculturally useful compositions comprising one or more compounds of this invention which exhibit fungistatic or fungicidal function against one or more plant pathogen is a fungus. | 10-29-2009 |
20090270497 | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors - Described herein are compositions and methods for treating a subject suffering from a non-localized inflammatory condition (or any symptoms associated with such inflammation), including systemic inflammation, and inflammatory conditions affecting the large portions of or the whole body, or sepsis by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound that is a pan-HDAC inhibitor. Also described herein are methods for decreasing iNOS and cytokine expression by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound that is a pan-HDAC inhibitor. | 10-29-2009 |
20090292014 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS - The invention relates to novel benzofuran derivatives, processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders | 11-26-2009 |
20090312415 | Remedy/preventive for vascular disorders and hypertension and method of screening the same - It is intended to clarify a transportation system participating in the uric acid uptake in vascular smooth muscle cells (VSMCs) and provide a novel remedy, a preventive or a treating agent for vascular disorders, hypertension and renal disorders with the use of a drug participating in this transportation system. It is also intended to provide a novel screening system for a remedy, a preventive or a treating agent for vascular disorders, hypertension and renal disorders with the use of such a transportation system. Namely, a medicinal composition for healing, preventing or treating vascular disorders, hypertension and renal disorders which comprises a drug having an effect of inhibiting the uric acid uptake by a uric acid transporter URAT1 and a pharmaceutically acceptable carrier; and a method of screening a substance efficacious for healing, preventing or treating vascular disorders, hypertension and renal disorders which comprises using a cell line expressing URAT1 in the presence or absence of a test compound and assaying the uric acid uptake level, cell proliferation ability or the amount of a monocyte chemotactic factor produced by the cells. | 12-17-2009 |
20100004328 | COMPOUND, Alpha1 ADRENERGIC RECEPTOR ANTAGONISTIC AGENT, AND COMPOSITION - A novel compound, a novel α | 01-07-2010 |
20100016423 | USE OF DRONEDARONE FOR THE TREATMENT OF PATIENTS WITH ARRHYTHMIA AND HAVING AN INCREASE OF CREATININE LEVEL DUE TO DRONEDARONE ADMINISTRATION - Methods of using dronedarone or a pharmaceutically acceptable salt thereof for the treatment of patients with arrhythmia, said patients having an increase of creatinine level due to dronedarone administration, said creatinine level increasing following dronedarone treatment initiation, said creatinine level increase reaching a plateau and being used as a new baseline, said creatinine level increase being reversible after dronedarone discontinuation. | 01-21-2010 |
20100035980 | ANTIPARASITIC AGENTS - The present invention relates to compounds of the formula (I) | 02-11-2010 |
20100048694 | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY - Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto. | 02-25-2010 |
20100048695 | ANTI-FATIGUE AGENT - Anti-fatigue agents containing dioxabicyclo[3.3.0]octane derivatives such as sesamin which is an ingredient contained in sesame, as well as pharmaceutical compositions and physiologically functional foods that contain such anti-fatigue agents are disclosed. These compounds can safely be administered to humans and animals alike and hence allow for continued ingestion while proving effective in promoting an improvement of stamina, an increase of body strength, a relief of fatigue, and recovery from fatigue. | 02-25-2010 |
20100076073 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders - The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI that is citalopram or escitalopram. It has unexpectedly been shown that the combination has a synergistic and potentiated effect of either compound as monotherapy, resulting in an enhanced therapeutic effect at lower doses. | 03-25-2010 |
20100099756 | USES OF INCENSOLE, INCENSOLE ACETATE AND DERIVATIVES THEREOF - The described subject matter relates to the use of incensole, incensole acetate, and derivatives thereof, for the treatment, prevention or amelioration of diseases or conditions, including inflammatory-associated conditions; a disease or condition where neuroprotection is required; and a disease or condition selected from depression, anxiety, obsessive compulsive behaviors, deterioration in cognitive function, and deterioration in neurobehavioral function. Pharmaceutical compositions and method of treatment, prevention or amelioration of the above-mentioned diseases or conditions are also provided. | 04-22-2010 |
20100137429 | COMPOSITION FOR TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION - The present invention provides a composition for transdermal or transmucosal administration, which is useful as an anti-Alzheimer's drug, an antiparkinson drug, an antidepressant, a psychoactive drug, or a therapeutic agent for drug dependence. The composition for transdermal or transmucosal administration comprising an effective dose of a racemate or an optically acceptable substance of 1-(benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable salt thereof and a vehicle, which can be administered without an invasion of skin and mucous membrane, is an excellent agent serving as an anti-Alzheimer's drug, an antiparkinson drug, an antidepressant, a psychoactive drug or a therapeutic agent for drug dependence, which can allow its active ingredient in a sufficient effective amount to stably arrive, through the skin and mucous membrane, at a body or a brain and is free of disadvantages such as a reduction in an active component caused by a first pass effect in a liver, as well as pains, damages or infections. | 06-03-2010 |
20100168228 | NOVEL CHEMOTHERAPEUTIC AGENTS AGAINST INFLAMMATION AND CANCER - Novel compounds, their methods of preparation and use in therapies related to cancer and inflammation are provided. Compounds comprise esters of cinnamic acid, vanillic acid and 4-hydroxy cinnamic acid and derivatives and salts thereof. Compounds with novel benzofuran lignan structure as a potent antimitotic agent and inducer of apoptosis are provided. Formulations and methods for treatment of diseases mediated by NF-kappaB are also provided. | 07-01-2010 |
20100240743 | CANNABINOID RECEPTOR MODULATOR - A cannabinoid receptor modulator containing a compound represented by Formula (I | 09-23-2010 |
20100261786 | PREDICTION OF SLEEP PARAMETER AND RESPONSE TO SLEEP-INDUCING COMPOUND BASED ON PER3 VNTR GENOTYPE - The invention relates to the prediction of a sleep parameter (e.g., sleep efficiency (SE), latency to persistent sleep (LPS), wake after sleep onset (WASO), total sleep time (TST)) of an individual and the response of such an individual to a sleep inducing compound based on the individual's PER3 variable number tandem repeat (VNTR) genotype. | 10-14-2010 |
20100292319 | PROCESS FOR PREPARING BENZOFURANS - There is provided a process for the preparation of a compound of formula (I), wherein R | 11-18-2010 |
20100292320 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS - The present disclosure provides a compound of general Formula (I) having enzyme inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. | 11-18-2010 |
20100298426 | THERAPEUTIC AGENT FOR SUBSTANCE DEPENDENCE - The present invention provides a therapeutic agent for substance dependence, which prevents relapse/recurrence of compulsive substance-taking behavior based on craving for addictive substances such as stimulant substances, opioids, barbiturate type anesthetics, hallucinogens, cocaine, hemp, cannabis, alcohol, or volatile organic solvents. (−)-1-(Benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable acid addition salt thereof is useful as a therapeutic agent for substance dependence, which prevents relapse/recurrence of compulsive substance-taking behavior associated with craving for addictive substances. | 11-25-2010 |
20110039926 | USE OF ENANTIOMER (1S, 2R) MILNACIPRAN HYDROCHLORIDE FOR THE PREVENTIVE TREATMENT OF SUICIDAL BEHAVIOUR IN DEPRESSED PATIENTS - The invention concerns the substantially pure (1S,2R) enantiomer of milnacipran hydrochloride for its use for treating patients suffering from psychiatric disorders, while reducing the risk of suicidal behaviour or ideation in said patients, and/or for limiting the risk of suicidal behaviour induced by the treatment with one or several SSRIs or other actual anti-depressants. | 02-17-2011 |
20110046218 | CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE - The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet. | 02-24-2011 |
20110054016 | METHOD FOR MODULATING CLAUDIN MEDIATED FUNCTIONS - Disclosed is a method for modulating a claudin-mediated function in a mammalian subject which comprises administering to a subject in need thereof an effective amount of a specific fatty acid derivative. The application also discloses a method for treating a dermatological disease and a method for modulating an expression of a claudin in a mammalian subject using the same fatty acid derivative as above. | 03-03-2011 |
20110124724 | USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR REGULATING THE POTASIUM LEVEL IN THE BLOOD - Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in regulating the potassium level in the blood. | 05-26-2011 |
20110136899 | COMBINATION OF DRONEDARONE WITH AT LEAST ONE DIURETIC, AND THERAPEUTIC USE THEREOF - The disclosure relates to a combination of dronedarone or a pharmaceutically salt thereof with at least one diuretic, and to the therapeutic use thereof. | 06-09-2011 |
20110144199 | METHODS FOR TREATING ATRIAL FIBRILLATION - The subject invention provides methods for reducing atrial fibrillation (AF) episode duration, methods for reducing stroke rate, methods for increasing time in normal sinus rhythm (NSR), methods for preventing atrial remodeling, and methods for reversing atrial remodeling, all comprising administering an amount of budiodarone effective to reduce AF episode duration. | 06-16-2011 |
20110166220 | DRONEDARONE FOR THE PREVENTION OF PERMANENT ATRIAL FIBRILLATION - Methods of using dronedarone in the prevention of permanent atrial fibrillation. | 07-07-2011 |
20110166221 | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVERSION - Methods of using dronedarone in the prevention of cardioversion. | 07-07-2011 |
20110196032 | Pharmaceutical Dosage Form of an Antidepressant - The present invention relates to pharmaceutical dosage forms of an antidepressant. More particularly, the present invention relates to pharmaceutical dosage forms of Escitalopram oxalate. The present invention also relates to a process for the preparation of pharmaceutical dosage forms of Escitalopram oxalate. | 08-11-2011 |
20110207811 | USE OF CELIVARONE FOR REDUCING OCCURRENCES OF CARDIOVASCULAR HOSPITALIZATION - The invention relates to a method of reducing occurrences of cardiovascular hospitalization of a patient by administering to the patient a pharmaceutically effective dose of the compound celivarone, or a pharmaceutically acceptable salt thereof. | 08-25-2011 |
20110213027 | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY - Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto. | 09-01-2011 |
20110224294 | CINAMIC COMPOUNDS AND DERIVATIVES THEREFROM FOR THE INHIBITION OF HISTONE DEACETYLASE - The invention relates to a compound represented by the following formula (I): | 09-15-2011 |
20110230552 | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION OF STROKE OR TRANSIENT ISCHEMIC ATTACK - Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack. | 09-22-2011 |
20110230553 | CRYSTALLIZED FORM OF DRONEDARONE BASE - The invention relates to a novel crystallized form of dronedarone base, to its process of preparation and to pharmaceutical compositions containing said novel crystallized form. | 09-22-2011 |
20120046356 | NEW PROCESS FOR PREPARING DIKETONES AND MEDICAMENTS - There is provided a process for the preparation of a compound of formula (III), wherein X and Y are as described in the description. Such compounds may, for example, be useful intermediates in the synthesis of drugs such as Dronedarone. There is also provided a process for the preparation of a compound of formula (I). | 02-23-2012 |
20120059053 | COMPOUNDS OF 2,3-DIHYDRO-BENZOFURAN - This invention provides new 2,3-dihydro-benzofuran compounds, their use for the treatment or prevention of melatoninergic disorders and its compositions. | 03-08-2012 |
20120095093 | ANTIFUNGAL COMPOUNDS - Antifungal compounds having a benzofuran structure. Antifungals exhibit much less toxicity to human cells than amiodarone. These compounds are useful alone or in combination with other compounds having antifungal activity. Compounds of this invention exhibit synergistic antifungal activity in combination with antifungal amiodarone compounds. The invention provides pharmaceutical compositions useful for treating fungal infections, methods for treating fungal infections and compounds useful in such compositions for treating fungal infections. Compounds of this invention are further useful as antifungal agents for the prevention and or treatment of fungal infections in plants. The invention includes agriculturally useful compositions comprising one or more compounds of this invention which exhibit fungistatic or fungicidal function against one or more plant pathogen is a fungus. | 04-19-2012 |
20120122971 | NEW PROCESS FOR PREPARING HYDROXYLAMINES AND MEDICAMENTS - There is provided a process for the preparation of a compound of formula II, | 05-17-2012 |
20120136050 | USE OF A MELATONIN AGONIST FOR THE TREATMENT OF SLEEP DISORDERS INCLUDING PRIMARY INSOMNIA - Embodiments of the invention include the treatment of a sleep disorder comprising the administration of N-[[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cycloproply]methyl]propanamide or a salt, stereoisomer, solvate, or hydrate thereof, in amorphous or crystalline form. | 05-31-2012 |
20120142768 | FORMULATIONS INCLUDING AMIODARONE AND SALTS THEREOF AND METHODS OF THEIR MANUFACTURE AND USE - The invention encompasses ready to administer liquid formulations including amiodarone and a substituted cyclodextrin. The invention also encompasses methods of making the liquid formulations to provide acceptable concentrations of amiodarone suitable for parenteral administration. The liquid formulations of the invention are formulations included, for example, in a ready to use intravenous bag, bottle or syringe. | 06-07-2012 |
20120157521 | TREATMENT OF MACULAR DEGENERATION - The present invention relates generally to methods for treating macular degeneration, and in particular age-related macular degeneration, involving the use of specific benzofuran based compounds. | 06-21-2012 |
20120190739 | EP2 AND EP4 AGONISTS AS AGENTS FOR THE TREATMENT OF INFLUENZA A VIRAL INFECTION - The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof. | 07-26-2012 |
20120190740 | USE OF DRONEDARONE FOR THE PREPARATION OF A DRUG FOR USE IN THE MANAGEMENT OF THE RISK OF LIVER INJURY - The present disclosure concerns methods of managing the risk of liver injury in patients receiving treatment with dronedarone or pharmaceutically acceptable salts thereof. | 07-26-2012 |
20120329867 | USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR THE PREPARATION OF A MEDICAMENT FOR ADMINISTRATION SHORTLY AFTER AMIODARONE DISCONTINUATION - The present invention concerns the use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention and/or treatment of patients with atrial fibrillation (AF) or atrial Flutter (AFL), shortly after discontinuation of a previous treatment with amiodarone. | 12-27-2012 |
20130005800 | COMPOSITION FOR TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION - The invention provides a composition for transdermal or transmucosal administration useful as an anti-Alzheimer's drug, an antiparkinson drug, an antidepressant, a psychoactive drug, or to treat drug dependence. The composition has an effective dose of a racemate or an optically acceptable substance of 1-(benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable salt thereof and a vehicle, which can be administered without an invasion of skin or mucous membrane. The composition enables its active ingredient to stably arrive in a sufficient effective amount through the skin and mucous membrane to the body or brain. The composition is free of disadvantages such as a reduction in an active component caused by a first pass effect in the liver, as well as pain, damage or infection. | 01-03-2013 |
20130018093 | NOVEL EPOPROSTENOL FORMULATION AND METHOD OF MAKING THEREOF - This invention relates to a stable epoprostenol composition that can be combined with commercially available IV fluids and can be administered in its reconstituted and/or diluted form under ambient conditions of about 15-30° C. for greater than 24 hours. The composition preferably contains (a) epoprostenol or a salt thereof; (b) a alkalinization agent; and (c) a base, such that when reconstituted or in solution, the solution has a pH>11. Methods for making the lyophilized composition are also disclosed. | 01-17-2013 |
20130041025 | COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS, HAIR THINNING, AND HAIR COLOR LOSS - Described herein are compositions including prostaglandin analogs including prostamides and methods for using these compositions for increasing eyelash and eyebrow growth and hair growth on the scalp. | 02-14-2013 |
20130116316 | Solid Pharmaceutical Compositions Containing Benzofuran Derivatives - The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients. | 05-09-2013 |
20130123353 | DRONEDARONE SOLID DISPERSION AND PREPARATION METHOD THEREOF - A dronedarone solid dispersion and preparation method thereof are disclosed. The solid dispersion is composed of active ingredient dronedarone or its pharmaceutically acceptable salt and a carrier material, wherein the carrier material is povidone, copovidone, hydroxypropyl cellulose, or a mixture thereof. | 05-16-2013 |
20130143960 | NOVEL SEROTONIN REUPTAKE INHIBITORS AS DRUGS HAVING PERIPHERAL-SYSTEM-RESTRICTED ACTIVITY - Serotonin reuptake inhibitor compounds which are designed to exert serotonin uptake inhibitory activity in the peripheral system while being devoid of CNS activity, and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with peripheral serotonin levels and/or activity, and/or platelet aggregation. | 06-06-2013 |
20130190393 | USES OF INCENSOLE, INCENSOLE ACETATE AND DERIVATIVES THEREOF - The described subject matter relates to the use of incensole, incensole acetate, and derivatives thereof, for the treatment, prevention or amelioration of diseases or conditions, including inflammatory-associated conditions; a disease or condition where neuroprotection is required; and a disease or condition selected from depression, anxiety, obsessive compulsive behaviors, deterioration in cognitive function, and deterioration in neurobehavioral function. Pharmaceutical compositions and method of treatment, prevention or amelioration of the above-mentioned diseases or conditions are also provided. | 07-25-2013 |
20130197076 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 08-01-2013 |
20130217763 | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY - Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto. | 08-22-2013 |
20130225673 | DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION - A compound represented by the general Formula I: | 08-29-2013 |
20130245115 | PHARMACEUTICAL COMPOSITION AND DOSAGE FORM COMPRISING DRONEDARONE, AND PREPARATION METHOD THEREOF - The disclosure relates to a pharmaceutical composition for oral administration, containing, as active principle, a benzofuran derivative having antiarrhythmic activity, in particular dronedarone and the pharmaceutically acceptable salts thereof, and at least one lipid carrier, said pharmaceutical composition being intended to be used in unit dosage form of the capsule type, in particular with a hard shell. This pharmaceutical composition and the dosage form comprising such a composition aim to limit the meal time effect following oral administration in humans. The lipid carrier allows: the solubilization of the active principle of the invention; and the shielding thereof from the negative effects of pH in the intestinal tract, thereby allowing same to be spared from the meal effect to a significant extent. | 09-19-2013 |
20130261177 | COMPOUNDS CAPABLE OF MODULATING/PRESERVING ENDOTHELIAL INTEGRITY FOR USE IN PREVENTION OR TREATMENT OF ACUTE TRAUMATIC COAGULOPATHY AND RESUSCITATED CARDIAC ARREST - The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC. | 10-03-2013 |
20130267589 | FUSED CYCLIC COMPOUNDS - The present invention provides a compound represented by the formula (I): | 10-10-2013 |
20130274325 | Fluorinated Benzofuran Derivatives - The invention relates to fluorinated compounds and their use in the field of pathological syndromes of the cardiovascular system. Novel fluorinated benzofuran derivatives of amiodarone and pharmaceutically acceptable salts or solvates thereof and their use for the treatment of arrhythmias are described. | 10-17-2013 |
20130274326 | EXTRACT OF EUODIA SUAVEOLENS SCHEFF, REPELLENT COMPOSITIONS AND USE THEREOF - The invention relates to an extract of | 10-17-2013 |
20130289106 | CINNAMIC ACID-BASED OLIGOMERS AND USES THEREOF - Cinnamic acid-based oligomers and therapeutic uses thereof are provided. The oligomers are used as anti-inflammation agents, inhibitors of elastase and anti-oxidants, and in some cases (e.g. the treatment of lung disorders such as lung cancer) all three activities are simultaneously beneficial. Subsets of the oligomers (e.g. β-O4 and β-5 trimers and tetramers) are used as anticoagulants. | 10-31-2013 |
20130317100 | PROCESS FOR THE PREPARATION OF 3-AROYL-5-AMINOBENZOFURAN DERIVATIVES - The present invention relates to a process for the preparation of 3-aroyl-5-aminobenzofuran derivatives useful as antiarrhythmic drugs which avoids the use of nitro intermediates. | 11-28-2013 |
20130317101 | SINGLETON INHIBITORS OF SUMOYLATION ENZYMES AND METHODS FOR THEIR USE - According to the embodiments described herein, a SUMOylation inhibitor compound comprising a singleton scaffold is provided. In some embodiments, a method for inhibiting a SUMOylation enzyme in a cell is provided. Such a method may include administering a SUMOylation inhibitor compound to the cell. In some aspects, the SUMOylation enzyme is SUMO E1 or SUMO E2. In some aspects, the method may be used to inhibit a cancer cell in vitro (e.g., grown in culture) or in vivo (e.g., as part of a tumor in a subject). In other embodiments, a method for treating a cancer, degenerative diseases and viral infection is provided. Such a method may include administering an effective amount of a pharmaceutical composition to a subject having the cancer. The pharmaceutical composition may include a singleton SUMOylation inhibitor compound. In some embodiments, the method for treating a cancer may further comprise administering one or more DNA-damaging therapy in combination with administration of the pharmaceutical composition. | 11-28-2013 |
20140005260 | METHOD FOR INHIBITING CANCER METASTASIS BY AMIODARONE | 01-02-2014 |
20140024706 | COMPOSITION COMPRISING SCIRPUSIN A AND SCIRPUSIN B AND ANTI-ADIPOGENESIS/ANTI-OBESITY POTENTIAL THEREOF - Disclosed is a composition comprising scirpusin A and scirpusin B and anti-obesity potential thereof. Also disclosed are methods of inhibiting adipogenesis using a composition comprising scirpusin A and scirpusin B. The present invention also disclosed methods of therapeutically managing obesity in mammals using a composition comprising scirpusin A and scirpusin B. Still further, the present invention also relates to a method of obtaining compositions comprising A. scirpusin A and scirpusin B and B. piceatannol and its dimers scirpusin A and scirpusin B through bioactivity guided fractionation of the rhizomes of | 01-23-2014 |
20140039049 | COMPOSITION CONTAINING SCIRPUSIN B, AND PROCESS FOR PRODUCING COMPOSITION CONTAINING SCIRPUSIN B - Provided are: a composition containing scirpusin B, which is a composition derived from a natural material and contains scirpusin B at a high content; and a process for producing the composition containing scirpusin B.A composition containing scirpusin B is produced by the extraction from a passion fruit seed. In the extraction of scirpusin B, the passion fruit seed is crushed, and subsequently at least one solvent selected from a hydrous alcohol solvent and a hydrous ketone solvent is added to the crushed product to thereby extract scirpusin B into the solvent. | 02-06-2014 |
20140080904 | Cinnamic Acid-Based Oligomers and Uses Thereof - Cinnamic acid-based oligomers and therapeutic uses thereof are provided. The oligomers are used as anti-inflammation agents, inhibitors of elastase and anti-oxidants, and in some cases (e.g. the treatment of lung disorders such as lung cancer) all three activities are simultaneously beneficial. Subsets of the oligomers (e.g. β-O4 and β-5 trimers and tetramers) are used as anticoagulants. | 03-20-2014 |
20140088189 | METHODS FOR REDUCING THE RISK OF AN ADVERSE DRONEDARONE / BETA-BLOCKERS INTERACTION IN A PATIENT SUFFERING FROM ATRIAL FIBRILATION - The disclosure relates to a method for managing the risk of dronedarone/beta-blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a beta-blockers treatment, by performing the following steps:
| 03-27-2014 |
20140128460 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE - Inhibitors of EYA tyrosine phosphatase are provided herein, as well as pharmaceutical compositions and methods relating thereto. | 05-08-2014 |
20140148507 | PHARMACEUTICAL COMPOSITION AND SOLID GALENIC FORM HAVING A HIGH DRONEDARONE CONTENT, AND METHOD FOR PREPARING SAME - The present invention relates to pharmaceutical compositions to be used, in a solid galenic form, for oral administration, and primarily including dronedarone and/or at least one of the derivatives thereof, as well as to solid galenic forms manufactured as such from said compositions, preferably in the form of tablets or capsules. The present invention also relates to a method for preparing such solid galenic forms using a hot-melt process. | 05-29-2014 |
20140148508 | C-3 SUBSTITUTED BICYCLOOCTANE BASED HIV PROTEASE INHIBITORS - C3-functionalized-cyclopentanyltetrahydrofuranyl carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are described. Compositions comprising the disclosed compound and methods of using the compounds and/or compositions for treating patients infected with HIV are also described. | 05-29-2014 |
20140187626 | OXANORBORNADIENE DERIVATIVES AND THEIR ANTICANCER ACTIVITIES - The present invention relates to chemical entities originated from natural sources and further synthesized for therapeutic uses. More particularly, the present invention relates to norcantharidin analogues synthesized by a transition metal-catalyzed alkynylation of oxanorbornadiene derivatives and their antitumor effects. | 07-03-2014 |
20140206761 | PROCESS FOR PREPARING HYDROXYLAMINES AND MEDICAMENTS - There is provided a process for the preparation of a compound of formula II, | 07-24-2014 |
20140249215 | NEW SALT OF ABEXINOSTAT, ASSOCIATED CRYSTALLINE FORM, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Abexinostat tosylate of formula (II): | 09-04-2014 |
20140275238 | INHIBITION OF NEOVASCULARIZATION BY INHIBITION OF PROSTANOID IP RECEPTORS - There are provided inter alia methods and compounds useful for decreasing choroidal neovascularization in a subject in need thereof. | 09-18-2014 |
20140275239 | Dronedarone Formulation - Dronedarone formulations. Formulations of dronedarone are disclosed that provide consistent release and absorption of dronedarone that is independent of food ingestion. The disclosed formulation achieves this result through the inclusion of rate-controlling polymers, such as cellulose derivatives, acrylic polymers, and natural polymers. The dosage form may be prepared through blending, dry granulation, or wet granulation, followed by compression into a tablet. | 09-18-2014 |
20140296330 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 10-02-2014 |
20140296331 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 10-02-2014 |
20140296332 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 10-02-2014 |
20140303245 | Sustained Release Composition of Prostacyclin - The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension. | 10-09-2014 |
20140309296 | BUDIODARONE FORMULATIONS - The present invention relates to budiodarone formulations which comprise a solution comprising benzyl alcohol and budiodarone, wherein the budiodarone has an aqueous solubility of about 200 mg/ml to about 1250 mg/ml when contacted with an aqueous solution. The budiodarone formulations can be highly concentrated and stored with stability, yet the formulations are also dilutable and can be delivered to a subject with ease and immediacy. | 10-16-2014 |
20140357710 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS - Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm. | 12-04-2014 |
20140371307 | SIRT 1 ACTIVATOR INCLUDING SYRINGARESINOL - The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases. | 12-18-2014 |
20150080464 | MELATONIN AGONIST TREATMENT - Melatonin Agonist, MA-1, is administered at effective doses. | 03-19-2015 |
20150313221 | ANTIMICROBIAL FERULIC ACID DERIVATIVES AND USES THEREOF - Antimicrobial diferulates, compositions containing same, and uses of same for inhibiting growth of microorganisms. The antimicrobial diferulates can be used alone or in combination with other antimicrobial agents to inhibit growth of microorganisms such as fungi, oomycetes, and other microorganisms having a glucan-containing cell wall. The antimicrobial diferulates can be included in pharmaceutical compositions for treatment of animals or included in agricultural compositions for treatment of plants, crops, and soils. | 11-05-2015 |
20150315167 | NEW SALT OF ABEXINOSTAT, ASSOCIATED CRYSTALLINE FORM, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Abexinostat tosylate of formula (II): | 11-05-2015 |
20150328181 | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY - Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto. | 11-19-2015 |
20150366501 | WHITE MATTER DIFFUSION TENSOR IMAGING TEST TO PREDICT TREATMENT OUTCOMES IN MEDICAL TREATMENT - The present invention relates to the field of biomarkers and in particular to their utilisation in treatment. Embodiments of the invention have been particularly developed as biomarkers enabling optimisation of treatment regimes and as uses of the biomarkers in tests for the prediction of optimised treatments and treatment outcomes in the treatment of Major Depressive Disorder (MDD). | 12-24-2015 |
20150370965 | MULTIPLE BIOMARKER PANELS TO STRATIFY DISEASE SEVERITY AND MONITOR TREATMENT OF DEPRESSION - Materials and methods for identifying and measuring pharmacodynamic biomarkers of neuropsychiatric disease (e.g., major depressive disorder), stratifying disease severity, and monitoring a subject's response to treatment are provided. | 12-24-2015 |
20160045468 | NOVEL THERAPEUTIC TARGET FOR THE TREATMENT OF CANCERS AND RELATED THERAPIES AND METHODS - Disclosed herein are compositions and methods for treating or preventing certain cancers in a subject. In certain embodiments such compositions and methods generally relate to the use of G-coupled protein receptor 40 (GPR40) agonists to inhibit the growth or induce apoptosis of certain cancer cells. The compositions and related methods disclosed herein may be used to treat subjects affected by cancers, such as melanoma, medullary thyroid carcinoma, malignant peripheral nerve sheath tumors and neuroblastoma, and to reduce the incidence of metastases in such affected subjects. | 02-18-2016 |
20160052904 | USE OF SMALL MOLECULE INHIBITORS TARGETING EYA TYROSINE PHOSPHATASE - Inhibitors of EYA tyrosine phosphatase having the structure of Formula I are provided herein. The compounds are useful for the treatment of certain proliferative diseases and cancer. | 02-25-2016 |
20160130219 | METABOLITES AND OXIMES WITH VASODILATOR AND HYPOTENSIVE ACTIVITY - Semi-synthetic oximes derived from metabolites extracted from medicinal plants, | 05-12-2016 |
20160198706 | EXTRACT OF EUODIA SUAVEOLENS SCHEFF, REPELLENT COMPOSITIONS AND USE THEREOF | 07-14-2016 |
20170233403 | PHILLYGENIN IBUPROFEN ESTER, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 08-17-2017 |